Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Abramson Cancer Center at Penn Medicine
Hoffmann-La Roche
Immuneering Corporation
Imugene Limited
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Icahn School of Medicine at Mount Sinai
Mural Oncology, Inc
ZielBio, Inc.
AIO-Studien-gGmbH
Tracon Pharmaceuticals Inc.
M.D. Anderson Cancer Center
Acrotech Biopharma Inc.
H. Lee Moffitt Cancer Center and Research Institute
Abramson Cancer Center at Penn Medicine
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Celldex Therapeutics
Silence Therapeutics GmbH
Memorial Sloan Kettering Cancer Center
University of Chicago
Pfizer